GNF-5

GNF-5, the N-hydroxyethyl carboxamide analog of GNF-2, is an orally active Bcr-Abl inhibitor. GNF-5 has Bcr-Abl inhibition activity with an IC50 value of 0.22 μM. GNF-5 has good favorable pharmacokinetic properties. GNF-5 can be used for the research of kinds of cancer including chronic myelogenous leukemia (CML) and breast cancer[1][2].

Product Specifications

CAS Number

[778277-15-9]

UNSPSC

12352005

Hazard Statement

H301, H319

Target

Bcr-Abl

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/GNF-5.html

Purity

99.95

Solubility

DMSO : ≥ 49 mg/mL

Smiles

FC(F)(F)OC(C=C1)=CC=C1NC2=NC=NC(C3=CC=CC(C(NCCO)=O)=C3)=C2

Molecular Formula

C20H17F3N4O3

Molecular Weight

418.37

Precautions

H301, H319

References & Citations

[1]Zhang J, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28;463 (7280) :501-6.|[2]Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9 (31) :22158-22183.